EyePoint (EYPT) Capital Expenditures (2010 - 2026)
EyePoint (EYPT) posted Capital Expenditures of $99000.0 for Q1 2026, down 96.9% sequentially from $3.2 million in Q4 2025, and up 125.0% YoY from $44000.0 in Q1 2025.
Analysis
EyePoint (EYPT) Capital Expenditures (2010 - 2026) Analysis & Trends
EyePoint has reported Capital Expenditures for 17 years, with the latest figure at $99000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 125.0% year-over-year to $99000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 6.35% YoY) and the FY2025 annual result came in at $3.3 million, down 19.05% from the prior year.
- Capital Expenditures declined to $99000.0 in Q1 2026 per EYPT's latest filing, from $3.2 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $3.2 million in Q4 2025 and troughed at -$484000.0 in Q2 2023.
- A 5-year average of $638733.3 and a median of $218000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 814.5% in 2022, then slumped 322.02% in 2023.
- Over 5 years, Capital Expenditures stood at $585000.0 in 2022, then sank by 182.74% to -$484000.0 in 2023, then jumped by 436.78% to $1.6 million in 2024, then jumped by 95.95% to $3.2 million in 2025, then slumped by 96.9% to $99000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $99000.0, $3.2 million, and $24000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 64,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 64,000.00 |
| Mar 31, 2026 | 3.36 Mn |
| Dec 31, 2025 | 986,000.00 |
| Sep 30, 2025 | 798,000.00 |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 276,000.00 |
| Dec 31, 2024 | 2.16 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | 883,000.00 |
| Sep 30, 2023 | 1.72 Mn |
| Jun 30, 2023 | 396,000.00 |
| Mar 31, 2023 | 484,000.00 |
| Dec 31, 2022 | 585,000.00 |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 218,000.00 |
| Mar 31, 2022 | 149,000.00 |
| Sep 30, 2021 | 131,000.00 |
| Jun 30, 2021 | 25,000.00 |